MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber’s Congenital … – PR Newswire (press release)
|
MeiraGTx Presents Preclinical Data on its Ocular Gene Therapy Studies for the Treatment of Leber's Congenital …
PR Newswire (press release) NEW YORK and BERLIN, Oct. 17, 2017 /PRNewswire/ — MeiraGTx, a New York and London based gene therapy company, today announced the presentation of preclinical data from studies in animal models of Leber's congenital amaurosis (LCA2), … |
